drugset
drugset / Trial / NCT01562041

Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

NCT01562041 ↗

Phase 2 Terminated 14 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelOther

Summary

The study was designed to evaluate the use of ETT electrocardiogram (ECG) indices as biomarkers in the assessment of atherosclerotic coronary vascular disease (ASCVD).

Timeline

Start
2012-03-09
Primary completion
2014-01-02
Completion
2014-01-02

Drugs

EvaluationDrugModalityDoseRoute
Background Ranolazine Small molecule 500 mg Oral

Indications

coronary atherosclerosis